Baxter International Inc.  (BAX) Trade Now »     Rate BAX  -  Discuss BAX  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

BAX: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

StreetBrief Valuation Model BAX

N/A

+16.05% in 152 days This one showed up last week, but we decided to double check the results.  Looks interesting. Continue reading »

Javelin Pharma: Late-Stage Pipeline Targets Pain BAX

73%

+11.63% in 241 days Javelin Pharma: Late-Stage Pipeline Targets Pain   Javelin Pharma (JAV) is focused on the late stage clinical development of three Phase 3 compounds while seeking partnerships for a non-dilutive source of funding. In mid-January, JAV established a partnership for Dyloject (injectable diclofenac) with Therabel Pharma to market the drug in Europe, where it is already approved for use.   http://biomedreports.com/fda-calendar.html   <> The deal is worth up to $71M (with $12M in upfront cash and $59.5M in sales/regulatory milestones) and extends Javelin'... Continue reading »

ETFI Health Innovators Index: Does R&D Lead to Higher Stock Prices? BAX

73%

-13.49% in 122 days (closed on 03/15/09) ETFI Health Innovators Index: Does R&D Lead to Higher Stock Prices? <> <> The accompanying table includes statistics and the top five rated companies in the ETFI Global Health Innovators Index of companies with market caps over $100M which received FDA approval in the trailing 12-month period for either an original new drug or medical device product. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for existing produc... Continue reading »

Expanding Defensive Growth Index into Europe BAX

73%

+0.12% in 20 days (closed on 11/12/08) Expanding Defensive Growth Index into Europe <> <> The accompanying table presents an updated version of the ETFI Highly Defensive PerformIdex, which is expanded to 40 companies with market caps of at least $10B from the industry groups listed below. This defensive growth index is heavily weighted in consumer staples and healthcare and is now structured to include companies based in Europe, in addition to the United States and Canada. Compared to the previous version, this index has a lower beta and higher average market cap and adds European companie... Continue reading »

Bullish on BAX ... BAX

62%

-12.07% in 486 days Analysts' Recommendation: Buy 30 Days Ago: Buy Analysts' Target: $70 Analysts' Targets Leerink Swann & Company $70 Outperform Monday, June 23, 2008 Baxter International, Inc. operates as a healthcare company worldwide. It offers medical devices, pharmaceuticals, and biotechnology products for the treatment of hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company operates through three segments: BioScience, Medication Delivery, and Renal. The BioScience segment manufactures ... Continue reading »

From the Blogosphere

Haemonetics Reports Strong Results – Analyst Blog

38%

Haemonetics Corporation (HAE) reported strong results for the second quarter of fiscal 2010. Earnings per share were 69 cents, beating the Zacks Consensus Estimate of 65 cents and the year-ago earnings of 58 cents. Sales Total revenues in the reported quarter were $157 million, increasing 8% year over year. Excluding a favorable foreign currency translation (FX), revenues increased 6% year over year. On a geographic basis, U.S. sales represented roughly 48% of total sales and increased 12.5% year over year. International sales increased 3.5% year over year. Plasma disposables revenues increase... Continue reading »

Baxter's key is versatility

Filed under: Baxter Intl (BAX), Stocks to Buy Although Baxter International's (NYSE: BAX) shares have underperformed since the Buy rating on March 13, 2009 at a price of $51.16, there's been no change in the company's positive operational characteristics, hence I'm Reiterating my Buy rating. And what's Baxter's key operational characteristic? Versatility. Baxter makes of a variety of medical products across three divisions, including drugs and vaccines, dialysis equipment, and IV supplies. The company should record a FY2009 revenue increase of 2-4%, led by demand for recombinants, plasma prot... Continue reading »

Cord Blood Stocks: Cord Blood Transplants May Provide Cures for Babies While Still in the Womb

5 %

Duke University is studying the use of cord blood transplants in babies while still in the womb, in order to treat various metabolic disorders. The U.S. Food and Drug Administration has given approval for clinical trials. Cord blood is blood that comes from umbilical cords, and contains a large amount of hematopoietic stem cells. Specialized cord blood banks are available to store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Many parents have their newborn's cord blood preserved in the event it may be needed at some point in the future for tr... Continue reading »

DSW, Polaris, Fairchild Semiconductor, Cypress Semiconductor All Guide Higher

56%

TempurPedic Raises Guidance TempurPedic International Inc. (TPX) said it expects 2009 earnings of $1.00 to $1.05 per share on revenue of $790.0 million to $805.0 million. The company's previous guidance was earnings of $0.70 to $0.90 per share on revenue of $700.0 million to $740.0 million and the current consensus earnings estimate is $0.87 per share on revenue of $736.6 million for the year ending December 31, 2009. SuccessFactors Guides Higher SuccessFactors (SFSF) said it expects third quarter revenue of $38.2 million to $38.7 million. The company's previous guidance was revenue of $37.2 m... Continue reading »

Turnaround expert targets laggard pharmaceuticals BAX

-0.91% in 30 days Filed under: Newsletters, Abbott Laboratories (ABT), Baxter Intl (BAX), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Stocks to Buy "Being contrarians, we are always looking for laggard stocks with the potential to rebound," says turnaround expert George Putnam. In his The Turnaround Letter, the advisor reviews four medical and pharmaceutical stocks that have been among the worst performers in the S&P 100 since the market bottom. Despite their poor performance, he thinks they may be due for a rebound. <>"We think that investors who got left behind by the first leg of the market rally are s... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.